{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(12)"],"submitter":["Syed F"],"pubmed_abstract":["Objective This trial aimed to evaluate the safety and efficacy of pre-exposure prophylaxis (PrEP) with various hydroxychloroquine (HCQ) doses against a placebo among healthcare personnel (HCP) with high-risk exposure to coronavirus disease 2019 (COVID 19). Methods A phase II, randomized, placebo-controlled trial was conducted including 200 subjects with no active or past severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (antibody testing and reverse transcription-polymerase chain reaction (RT-PCR) were taken at the time of enrollment). Subjects of experimental groups one to three received HCQ in various doses and the control group received a placebo. The study outcomes in terms of safety and efficacy were monitored. Participants exhibiting COVID-19 symptoms were tested"],"journal":["Cureus"],"pagination":["e20572"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8776514"],"repository":["biostudies-literature"],"pubmed_title":["Pre-exposure Prophylaxis With Various Doses of Hydroxychloroquine Among Healthcare Personnel With High-Risk Exposure to COVID-19: A Randomized Controlled Trial."],"pmcid":["PMC8776514"],"pubmed_authors":["Syed F","Ashraf S","Arif MA","Hassan M","Arshad J","Niazi R","Batool S","Laila UE"],"additional_accession":[]},"is_claimable":false,"name":"Pre-exposure Prophylaxis With Various Doses of Hydroxychloroquine Among Healthcare Personnel With High-Risk Exposure to COVID-19: A Randomized Controlled Trial.","description":"Objective This trial aimed to evaluate the safety and efficacy of pre-exposure prophylaxis (PrEP) with various hydroxychloroquine (HCQ) doses against a placebo among healthcare personnel (HCP) with high-risk exposure to coronavirus disease 2019 (COVID 19). Methods A phase II, randomized, placebo-controlled trial was conducted including 200 subjects with no active or past severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (antibody testing and reverse transcription-polymerase chain reaction (RT-PCR) were taken at the time of enrollment). Subjects of experimental groups one to three received HCQ in various doses and the control group received a placebo. The study outcomes in terms of safety and efficacy were monitored. Participants exhibiting COVID-19 symptoms were tested","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-19T23:34:44.063Z","creation":"2025-04-19T23:34:44.063Z"},"accession":"S-EPMC8776514","cross_references":{"pubmed":["35103151"],"doi":["10.7759/cureus.20572"]}}